Regentis Biomaterials Ltd. Ordinary Shares (NY:RGNT)

2.395 -0.475 (-16.55%)

Streaming Delayed Price Updated: 1:00 PM EDT, May 4, 2026 Add to My Watchlist

Price and Volume

Volume	22,283
Open	2.400
Bid (Size)	2.390 (200)
Ask (Size)	2.400 (100)
Prev. Close	2.870
Today's Range	2.380 - 2.840
52wk Range	2.700 - 8.350
Shares Outstanding	24,114,610
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon

April 16, 2026

Via ACCESS Newswire

Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%

March 17, 2026

Via ACCESS Newswire

Performance

YTD	-64.8%	-64.8%
1 Month	-23.0%	-23.0%
3 Month	-58.8%	-58.8%
6 Month	-68.1%	-68.1%
1 Year	-68.1%	-68.1%

More News

Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update

February 24, 2026

Via ACCESS Newswire

Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair

February 19, 2026

Via ACCESS Newswire

Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs

February 17, 2026

Via ACCESS Newswire

Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial

February 04, 2026

Via ACCESS Newswire

Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method

January 20, 2026

Via ACCESS Newswire

Nano-Cap Regentis Biomaterials Stock Is Up Nearly 15% This Year: Why Retail Traders Are Swarming It ↗

January 16, 2026

Via Stocktwits

Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation

January 06, 2026

Via ACCESS Newswire

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Secures New U.S. Patent for GelrinC Liquid Formulation

January 05, 2026

Via Investor Brand Network

Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC

December 18, 2025

Via ACCESS Newswire

Regentis Biomaterials Commences Trading on NYSE: Set to Transform Cartilage Repair Market with Off-the-Shelf Regenerative Product

December 08, 2025

Via ACCESS Newswire

Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering

December 05, 2025

From Regentis Biomaterials Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Regentis Biomaterials Ltd. Ordinary Shares publicly traded?

Yes, Regentis Biomaterials Ltd. Ordinary Shares is publicly traded.

What exchange does Regentis Biomaterials Ltd. Ordinary Shares trade on?

Regentis Biomaterials Ltd. Ordinary Shares trades on the New York Stock Exchange

What is the ticker symbol for Regentis Biomaterials Ltd. Ordinary Shares?

The ticker symbol for Regentis Biomaterials Ltd. Ordinary Shares is RGNT on the New York Stock Exchange

What is the current price of Regentis Biomaterials Ltd. Ordinary Shares?

The current price of Regentis Biomaterials Ltd. Ordinary Shares is 2.395

When was Regentis Biomaterials Ltd. Ordinary Shares last traded?

The last trade of Regentis Biomaterials Ltd. Ordinary Shares was at 05/04/26 01:00 PM ET

What is the market capitalization of Regentis Biomaterials Ltd. Ordinary Shares?

The market capitalization of Regentis Biomaterials Ltd. Ordinary Shares is 57.75M

How many shares of Regentis Biomaterials Ltd. Ordinary Shares are outstanding?

Regentis Biomaterials Ltd. Ordinary Shares has 58M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.